Glioma Response to IDH Inhibition: Real-World Experience

Clin Cancer Res. 2023 Sep 22. doi: 10.1158/1078-0432.CCR-23-2164. Online ahead of print.ABSTRACTTreatment of IDH mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. IDH inhibition has a therapeutic benefit in patients with these tumors.PMID:37738033 | DOI:10.1158/1078-0432.CCR-23-2164

Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Rimas V Lukas Craig Horbinski Source Type: research